Clinical Impact and Cellular Mechanisms of Iron Overload-Associated Bone Loss
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Diseases/conditions with diverse etiology, such as hemoglobinopathies, hereditary hemochromatosis and menopause, could lead to chronic iron accumulation. This condition is frequently associated with a bone phenotype; characterized by low bone mass, osteoporosis/osteopenia, altered microarchitecture and biomechanics, and increased incidence of fractures. Osteoporotic bone phenotype constitutes a major complication in patients with iron overload. The purpose of this review is to summarize what we have learnt about iron overload-associated bone loss from clinical studies and animal models. Bone is a metabolically active tissue that undergoes continuous remodeling with the involvement of osteoclasts that resorb mineralized bone, and osteoblasts that form new bone. Growing evidence suggests that both increased bone resorption and decreased bone formation are involved in the pathological bone-loss in iron overload conditions. We will discuss the cellular and molecular mechanisms that are involved in this detrimental process. Fuller understanding of this complex mechanism may lead to the development of improved therapeutics meant to interrupt the pathologic effects of excess iron on bone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osf2/Cbfa1: A Transcriptional Activator of Osteoblast Differentiation
Ducy, P., Zhang, R., Geoffroy, V., Ridall, A. L., & Karsenty, G. (1997) · Cell · doi:10.1016/s0092-8674(00)80257-3 · Cited by 4,246 · cited 10×
“The absence of Runx2 in mice results impaired bone formation, the lack of differentiated osteoblasts, and eventually leads to death shortly after birth (Komori et al., 1997; Otto et al., 1997).”
BackgroundInfluentialKomori, T., Yagi, H., Nomura, S., Yamaguchi, A., Sasaki, K., Deguchi, K., Shimizu, Y., Bronson, R. T., Gao, Y.-H., Inada, M., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80258-5 · Cited by 4,244
Epidemiology and outcomes of osteoporotic fractures
Cummings, S. R., & Melton, L. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08657-9 · Cited by 3,821 · cited 1×
“Among postmenopausal white women the lifetime risk of hip fracture is 15–20%, and the risk of any osteoporotic fractures is about 50% (Cummings et al., 1989; Cummings and Melton, 2002).”
BackgroundA novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis
Feder, J. N., Gnirke, A., Thomas, W., Tsuchihashi, Z., Ruddy, D. A., Basava, A., Dormishian, F., Domingo, R., Ellis, M. C., Fullan, A., et al. (1996) · Nature Genetics · doi:10.1038/ng0896-399 · Cited by 3,664
Skeletal remodeling in health and disease
Zaidi, M. (2007) · Nature Medicine · doi:10.1038/nm1593 · Cited by 1,069 · cited 1×
“Bone is a metabolically active tissue that undergoes continuous remodeling with the involvement of osteoclasts that resorb mineralized bone, and osteoblasts that form new bone matrix (Zaidi, 2007).”
BackgroundMutations in HFE2 cause iron overload in chromosome 1q–linked juvenile hemochromatosis
Papanikolaou, G., Samuels, M. E., Ludwig, E. H., MacDonald, M. L. E., Franchini, P. L., Dubé, M.-P., Andres, L., MacFarlane, J., Sakellaropoulos, N., Politou, M., et al. (2004) · Nature Genetics · doi:10.1038/ng1274 · Cited by 974 · cited 2×
“Other types of hereditary hemochromatosis are caused by mutations in the transferrin receptor-2 gene (TfR2) (Camaschella et al., 2000), hemojuvelin gene (HJV) (Papanikolaou et al., 2004), hepcidin gene (HAMP) (Roetto et al., 2003), and the ferroportin gene (SCL40A1) (Pietrangelo, 2004).”
BackgroundMutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis
Roetto, A., Papanikolaou, G., Politou, M., Alberti, F., Girelli, D., Christakis, J., Loukopoulos, D., & Camaschella, C. (2003) · Nature Genetics · doi:10.1038/ng1053 · Cited by 860 · cited 2×
“, 2004), hepcidin gene (HAMP) (Roetto et al., 2003), and the ferroportin gene (SCL40A1) (Pietrangelo, 2004).”
BackgroundThe gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22
Camaschella, C., Roetto, A., Calì, A., De Gobbi, M., Garozzo, G., Carella, M., Majorano, N., Totaro, A., & Gasparini, P. (2000) · Nature Genetics · doi:10.1038/75534 · Cited by 803
Coordination of PGC-1β and iron uptake in mitochondrial biogenesis and osteoclast activation
Ishii, K.-A., Fumoto, T., Iwai, K., Takeshita, S., Ito, M., Shimohata, N., Aburatani, H., Taketani, S., Lelliott, C. J., Vidal-Puig, A., et al. (2009) · Nature Medicine · doi:10.1038/nm.1910 · Cited by 410 · cited 2×
“Tfr1-mediated iron uptake facilitated osteoclast differentiation and bone-resorbing activity, whereas iron chelation inhibited osteoclastic bone resorption (Ishii et al., 2009).”
BackgroundAssociation of age, sex, and race with body iron stores in adults: Analysis of NHANES III data
Zacharski, L. R., Ornstein, D. L., Woloshin, S., & Schwartz, L. M. (2000) · American Heart Journal · doi:10.1067/mhj.2000.106646 · Cited by 349
Cited by
The effect of abnormal iron metabolism on osteoporosis
Che, J., Yang, J., Zhao, B., Zhang, G., Wang, L., Peng, S., & Shang, P. (2020) · Biological Trace Element Research · doi:10.1007/s12011-019-01867-4 · Cited by 113
Iron, Zinc, Copper, Cadmium, Mercury, and Bone Tissue
Ciosek, Ż., Kot, K., & Rotter, I. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20032197 · Cited by 86
“Fe overload is associated with bone weakness, which is represented as reduced bone mass, osteopenia, osteoporosis, altered bone microarchitecture and biomechanics, and frequent bone fractures [36,37].”
BackgroundYang, J., Zhang, G., Dong, D., & Shang, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092608 · Cited by 54
Metadata
- Authors
- Jeney, V.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2017-02-21
- Volume
- 8
- Pages
- 77-77
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2589170665
- Cited by
- 163
- References
- 14
- FWCI
- 4.27
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.